Replimune Limited Ex. 2023 - Page 1
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`08/12-
`
`
`
`Harvey W.
`Cushing Professor
`
`Neurosurgery
`
`Harvard Medical School, Boston, MA
`
`Appointments at Hospitals/Affiliated Institutions
`
`07/95-12/95
`
`Neurosurgery
`
`07/98-02/04
`
`02/04-08/12
`
`Assistant
`Physician
`Associate
`Physician
`Physician
`
`Surgery
`
`Neurosurgery
`
`Massachusetts General Hospital,
`Boston, MA
`Massachusetts General Hospital,
`Boston, MA
`Wexner Medical Center, Columbus,
`OH
`Brigham & Women’s Hospital, Boston,
`MA
`
`08/12-
`
`Physician
`
`Neurosurgery
`
`Other Professional Positions
`
`
`
`1995-2005
`1997
`1997-2001
`1998
`2000-2005
`2001-
`2002
`
`2002-2008
`
`2005
`
`2006-
`2008,
`2010
`2006-
`
`2007-2012
`2008-2012
`2008-
`2009
`
`2010-2012
`2011-
`
`2012-
`
`2013-
`2013-
`2013-
`
`2014
`
`Biotechnology Consultant
`Biotechnology Consultant
`Biotechnology Consultant
`Biotechnology Consultant
`Scientific Review Board Member
`Scientific Advisory Council Member
`Member, Abstract Review Group
`
`Member, Extramural Subspecialty Writing
`Committee
`Invited Guest Examiner
`
`Scientific Advisory Committee Member
`
`Scientific Advisory Committee Member
`
`Data Monitoring Committee
`Biotechnology Consultant
`Scientific Advisory Board Member
`Invited Guest Examiner
`
`Biotechnology Consultant
`Scientific Executive Council
`
`Advisory Council Member
`
`Consultant
`Consultant
`Chair, Scientific Advisory Council
`
`Invited Guest Examiner
`
`Oxford Biomedica
`Millennium Pharmaceuticals
`Prestwick Scientific Capital
`Shanghai Biotech
`National Gene Vector Laboratories
`American Brain Tumor Association
`Fourteenth International Conference on
`Brain Tumor Research and Therapy
`American Board of Neurological
`Surgery
`American Board of Neurological
`Surgery
`Goldhirsh Foundation Brain Tumor
`Research Awards Program
`
`Neurosurgery Research and Education
`Foundation (NREF)
`Ceregene Corporation
`Ceregene
`Sontag Foundation
`American Board of Neurological
`Surgery
`Bexion
`Neurosurgery Research Education
`Foundation (NREF)
`National Institute of Neurological
`Disorders and Stroke (NINDS)
`DNATrix, Inc
`Alcyone Lifesciences, Inc
`Neurosurgery Research Education
`Foundation (NREF)
`American Board of Neurological
`Surgery
`
`2
`
`
`
`Replimune Limited Ex. 2023 - Page 2
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`2014-2015
`2015-present
`2015-2017
`2015-present
`2018-present
`2018
`2014-present
`2017
`2015
`2015
`2016
`2016
`2016
`2008
`2018-present
`
`Scientific Advisory Council Member
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`Consultant
`
`StemGen
`NanoTX
`Tocagen
`Alcyone Biosciences
`Insightec Inc
`Sigilon Therapeutics
`DNATrix Inc
`Ziopharm Oncology
`Cerebral Therapeutics
`Genenta
`Oncorus
`Merck
`Janssen
`Karcinolysis
`Advantagene Inc.
`
`Major Administrative Leadership Positions
`
`Local
`2003
`
`2003
`
`Organizer, 3rd Annual Carolyn Frye-
`Halloran Symposium in Neuro-Oncology
`
`Massachusetts General Hospital
`
`Conference Organizer, Monthly Lecture
`Series in Neuro-Oncology
`
`Massachusetts General Hospital
`
`2004-2012
`
`Director of Neurosurgical Services
`
`2004-2012
`
`Director, Dardinger Center for Neuro-
`oncology and Neurosciences
`
`2004-2012
`
`Co-Director, Viral Oncology Program,
`Comprehensive Cancer Center
`
`2004-2012
`
`Chairman
`
`2005-2012
`
`2006
`
`Director /Physician Leader, Neuroscience
`Signature Program (Currently this is a
`Neuroscience Institute)
`Panel Chair, Neurosciences and
`Neurosurgery Research, OSU Industry
`
`The Ohio State University Wexner
`Medical Center and Arthur G. James
`Cancer Hospital and Richard J. Solove
`Research Institute
`The Ohio State University Wexner
`Medical Center and Arthur G. James
`Cancer Hospital and Richard J. Solove
`Research Institute
`
`The Ohio State University Wexner
`Medical Center and Arthur G. James
`Cancer Hospital and Richard J. Solove
`Research Institute
`The Ohio State University Wexner
`Medical Center
`The Ohio State University Wexner
`Medical Center
`
`The Ohio State University Medical
`Center, Columbus, Ohio
`
`3
`
`
`
`Replimune Limited Ex. 2023 - Page 3
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`2012-
`
`2012-
`2012-
`2018-
`
`
`
`
`
`National
`
`2015
`
`
`
`International
`2014
`
`
`2015
`
`
`
`
`
`
`
`
`Dana Farber Cancer Institute
`
`Collaboration Symposium
`Surgical Director, Neuro-Oncology
`Program
`Co-Director, Institute for the Neurosciences Brigham & Women’s/Faulkner Hospital
`Chairman, Department of Neurosurgery
`Brigham & Women’s Hospital
`Co-Director, Grand Challenges in
`Brigham & Women’s Hospital / MIT
`Glioblastoma: The Blood-Brain Barrier: An
`Obstacle to effective therapies.”
`
`Course Director, Launching Effectiveness
`Research to Guide Practice in Neurosurgery
`
`NIH/NINDS, Washington, DC
`
`Course Director, 13th Annual International
`Neuro-Oncology Updates Symposium
`
`Course Director, 9th International
`Conference on Oncolytic Virus
`Therapeutics
`
`
`Brigham & Women’s Hospital
`
`
`Brigham & Women’s Hospital /
`Massachusetts General Hospital
`
`Committee Service
`
`Local
`
`
`2004-2012
`
`2005
`
`Space Planning Committee
`
`Neurology Chair Search Committee
`(recruited Dr. Michael Racke,
`Southwestern)
`
`2006-2012
`
`Neurosciences Graduate Studies Program
`
`2006-2012
`
`Center for Brain and Spinal Cord Repair
`
`2006
`
`Anesthesiology Chair Search Committee
`
`2006
`
`Chief of Pediatric Neurosurgery Search
`Committee
`
`The Ohio State University College of
`Medicine
`Committee Member
`
`The Ohio State University College of
`Medicine
`Head of Search Committee
`
`The Ohio State University Graduate
`School
`Executive Committee / Faculty
`
`The Ohio State University
`Executive Committee / Associate Member
`
`
`The Ohio State University College of
`Medicine
`Committee Member
`
`The Ohio State University College of
`Medicine
`
`4
`
`
`
`Replimune Limited Ex. 2023 - Page 4
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`2006
`
`2006
`
`2008
`
`2012-
`
`2012-
`
`2012-2013
`
`2012-
`
`2012-
`
`2012-
`
`2013-
`
`2013-
`
`2013-2014
`
`2013-2015
`
`2013-
`
`2014-2015
`
`Neuroscience Chair Search Committee
`
`Anesthesiology Chair Search Committee
`
`Radiation Oncology Chair Search
`Committee
`(recruited Dr. Arnab Chakravarti,
`Massachusetts General Hospital)
`Neuroscience Executive Committee
`
`BWPO Executive Committee
`
`Endovascular Disease Search Committee
`
`Care Improvement Council (CIC)
`
`Presidents Council
`
`DFCI Executive Committee
`
`
`Clinical Trials Portfolio Review Oversight
`Committee
`
`Committee Member
`The Ohio State University College of
`Medicine
`Committee Member
`The Ohio State University College of
`Medicine
`Committee Member
`The Ohio State University College of
`Medicine
`Head of Search Committee
`
`Brigham & Women’s Hospital
`Committee Member
`
`Brigham & Women’s Hospital
`Committee Member
`
`Brigham & Women’s Hospital
`Committee Chair
`
`Brigham & Women’s Hospital
`Committee Member
`
`Brigham & Women’s Hospital
`Committee Member
`
`Dana Farber Cancer Institute
`Committee Member
`
`Dana Farber Cancer Institute
`Committee Member
`
`Executive Committee for Clinical Research Dana Farber Cancer Institute
`Committee Member
`
`Harvard Medical School
`Committee Member
`
`Brigham and Women’s Hospital, Dana-
`Farber Cancer Institute, & Boston
`Children’s Hospital
`Committee Member
`
`Harvard Medical School
`Committee Member
`
`
`Brigham & Women’s Hospital
`Committee Chair
`
`
`Standing Committee on Promotions,
`Reappointments, and Appointments
`
`Radiation Oncology Chair Search
`Committee
`
`Department of Neurosurgery Executive
`Committee
`
`Spine Neurosurgery Search Committee
`
`5
`
`
`
`Replimune Limited Ex. 2023 - Page 5
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`2014-
`
`2014-2015
`
`2015-2015
`
`
`2015-
`
`2015-2016
`
`
`2016-2017
`
`2016-
`
`2017-
`
`
`2018-
`
`2019-
`
`
`
`Committee on Outside Activities
`
`Orthopedic Department Chair Search
`Committee
`
`Anesthesia Department Chair Search
`Committee
`
`Partners Committee on Senior
`Appointments (PCSA)
`
`
`Department of Surgery Chair Search
`Committee
`
`Neurosurgery Department Chair Search
`Committee
`
`Executive Medical Director of Surgical and
`Procedural Services
`
`Neurology Department Chair Search
`Committee
`
`Functional Neurosurgeon Search
`Committee
`
`Director, BWH Neurological Intensive
`Care Unit Search Committee
`
`Partners Healthcare System
`Committee Co-Chair
`
`Brigham & Women’s Hospital
`Committee Member
`
`Brigham & Women’s Hospital
`Committee Member
`
`Partners Healthcare System
`Committee Member
`
`
`Brigham & Women’s Hospital
`Committee Member
`
`Massachusetts General Hospital
`Committee Member
`
`Brigham and Women’s Hospital
`Committee Member
`
`Brigham and Women’s Hospital
`Committee Member
`
`Brigham and Women’s Hospital
`Committee Member
`
`Brigham and Women’s Hospital
`Committee Member
`
`National and International
`
`
`1997
`
`Committee on Herpes Simplex Virus
`(HSV) for Tumor Therapy
`
`1998
`
`Committee on Immunotherapy for Brain
`Tumors
`
`1999
`
`Abstract Review Committee
`
`2000
`
`Progress Review Committee on Brain
`Tumors
`
`National Cancer Institute/Cancer
`Therapy Evaluation Program
`(NCI/CTEP)
`Committee Member
`
`Preuss Foundation
`Committee Member
`
`International Herpes Simplex Virus
`Workshop
`Committee Member
`
`National Cancer Institute/National
`Institute of Neurological Disorders and
`Stroke (NCI/NINDS)
`Committee Member
`
`6
`
`
`
`Replimune Limited Ex. 2023 - Page 6
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`2001
`
`2008-
`
`2010-2013
`
`2012-2016
`2012-2014
`
`
`2015-
`
`2018-2018
`
`
`
`Committee on Gene Therapy for the
`Central Nervous System
`
`Sontag Founation
`
`Recombinant DNA Advisory Committee,
`Office of Biotechnological Affairs
`
`Advisory Council
`Search Committee for Editor-in-Chief
`
`
`Scientific Advisory Council
`
`American Association of Neurological
`Surgeons
`
`
`
`
`National Institute of Neurological
`Disorders and Stroke (NINDS)
`Committee Member
`
`Scientific Advisory Board
`
`National Institutes of Health (NIH)
`Committee Member
`
`NINDS, Washington, DC
`Journal of Neurosurgery
`Committee Chair
`
`Alliance for Cancer Gene Therapy
`
`Board of Directors – Division 8
`
`
`
`
`Professional Societies
`
`1990-
`
`Congress of Neurological Surgeons
`
`Member
`
`
`2006 Committee for Enhancement of
`Neurosurgical Research
`2010-2013 Nominating Committee
`American Association of Neurological
`Member
`Surgery/Congress of Neurological Surgery
`Joint Section on Tumors
`
`
`
`
`
`
`1999-2009 Executive Council Member
` 2001 Program Committee, Tumor Section
`2003 Program Committee, Tumor Section
`2004-2009 “Bylaws” Subcommittee, Tumor
`Section
`2011- Matrix Committee for Tumors, Tumor
`Section
`American Society for Gene/Cell Therapy Member
`
`
`
`
`2000 Abstract Review Group, Annual
`Meeting
`2001 Coordinating Reviewer, Abstract
`Review Group, Annual Meeting
`2003 Nominating Committee
`2008 Abstract Reviewer, Annual Meeting
`
`2011- Development Committee
`Member
`2006-2010 Awards Committee
`
`
`
`
`1990-
`
`
`
`
`
`
`
`
`1999-
`
`
`
`
`
`
`
`
`1999-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Society for Neuro-Oncology
`
`7
`
`
`
`Replimune Limited Ex. 2023 - Page 7
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`
`
`
`
`
`
`2001-
`
`
`
`
`
`
`
`2001-
`
`2001-
`2001-
`
`2003
`
`
`2005-
`
`
`
`
`
`2005-
`2006-
`
`2007-
`2013-
`2014-
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2006-2010 Education Committee
`2008- Executive Committee
`2008 Elected to Board of Directors
`2011-2013 Secretary/ Treasurer
`2012 Chairman, Scientific Program
`Committee, Annual Meeting
` 2013-2015 Vice President
`2015-2017 President
`American Association of Neurosurgery
`Member
`
`2001-2011 NREF SAC member
`2011-2012 Chair, J. Neurosurgery Editor in Chief
`Search Committee
`2013-2016 Nominating Committee
`2011-
`Chair, NREF Scientific Advisory
`
`Council
`2017-2018
`Board of Directors
`
`
`Member
`
`American Society for Experimental
`Neurotherapeutics
`American Society for Microbiology
`International Society for Neurovirology
`
`European Society for Gene Therapy
`
`
`Member
`Member
`
`Member
`
`2003 Vector Committee Member
`American Academy of Neurological Surgery Member
`
`
`
`
` 2011-2012 Chairman, Scientific Program
`Committee
`2013-2017 Treasurer
`2017-2018 President-Elect
`2018-2019 President
`American Society for Clinical Investigation Member
`Society of Neurological Surgeons
`Member
`2006-2010 Education Committee
`2007- Research Committee
`2010- Committee for Assessment of
`Subspecialty Training (CAST)
`2013- 2017 Chair, Research Committee
`
`2015- present Chair, H. Richard Winn Prize
`Committee
`
`2017-present Member-at-Large
`
`Member
`Neurosurgical Society of America
`World Academy of Neurological Surgery Member
`Institute of Medicine (IOM)/National
`Elected to Membership
`Academy of Medicine
`
`
`
`
`
`
`
`
`
`
`
`8
`
`
`
`Replimune Limited Ex. 2023 - Page 8
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`Grant Review Activities
`
`2001-2005
`
`2001-2005
`
`2002-2005
`
`2004, 2007
`
`2004
`
`2005-2009
`
`2005-2010
`
`Neurological Sciences and Disorders
`(NSD) Subcommittee B Study Section
`
`Molecular Genetics and Oncology Study
`Section
`
`Specialized Programs of Research
`Excellence (SPORE) Grants in Neuro-
`Oncology
`Developmental Therapeutics (DT),
`Program Project Grant (P01) cluster,
`Integrative Molecular Analysis
`Technologies (IMAT) Study Sections
`
`NCI Parent Committee (Scientific Review
`Council)/ Subcommittee D (Clinical
`Studies), Program Projects Grants
`(reviewing clinical/translational studies)
`
`Developmental Therapeutics (DT) Study
`Section
`
`Program Project Reviews (NCI - C and D) NCI/NIH
`Ad hoc consultant
`
`NINDS/NIH
`Ad hoc consultant
`
`
`
`American Cancer Society (ACS
`Member
`
`NCI/NIH
`Reviewer
`
`NCI/NIH
`Ad hoc Reviewer
`
`
`NCI/NIH
`Member
`
`NIH
`Member
`
`National Cancer Institute, Canada
`Ad hoc reviewer
`
`Alliance for Cancer Gene Therapy
`Ad hoc Reviewer
`
`NINDS
`Ad hoc Reviewer
`
`MD Anderson
`External Reviewer
`
`New York University
`External Reviewer
`
`2007
`
`Scientific Grant Committee
`
`2007
`
`Grant Committee
`
`2009
`
`Board of Scientific Councilors
`
`2010
`
`Division of Neuro-Oncology and of
`Neurosurgery
`
`2011
`
`Division of Neuro-Oncology
`
`Editorial Activities
`
`Ad Hoc Reviewer
`Cancer Gene Therapy
`
`9
`
`
`
`Replimune Limited Ex. 2023 - Page 9
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`Cancer Research
`Clinical Cancer Research
`Experimental Neurology
`Gene Therapy
`Human Gene Therapy
`Journal of Clinical Investigation
`Journal of Gene Medicine
`Journal of Neuro-oncology
`Journal of Neuropathology and Experimental Neurology
`Journal of Neurovirology
`Journal of Virology
`Life Sciences
`Molecular Cancer Therapy
`Molecular Pharmacology
`Molecular Therapy
`Nature
`Nature Biotechnology
`Nature Genetics
`Nature Medicine
`Neoplasia
`Neurosurgery
`Neurosurgical Focus
`Oncogene
`
`
`
`Other Editorial Roles
`1998-
`1998-
`2006-
`2005-
`2000-
`2005-
`2007-
`2007-2017
`
`2011-2012
`2014-
`
`
`
`Editorial Board
`Editorial Board
`Editorial Board
`Editorial Board
`Editorial Board
`Editorial Board
`Editorial Board
`Section Editor (Brain Tumors)
`
`Co-Chairman, Editorial Board
`Section Editor, Tumor
`
`Cancer Gene Therapy
`Journal of Neurovirology
`Journal of Robotic Surgery
`Molecular Therapy
`Neoplasia
`Neuro-oncology
`Journal of Neurosurgery
`Youmans Textbook of Neurosurgery, Sixth
`and Seventh editions (released 2012, 2017)
`Journal of Neurosurgery
`Neurosurgery
`
`
`Honors and Prizes
`
`1985
`
`Alpha Omega Alpha
`
`1988
`
`1988
`
`1992 – 1994
`1994
`
`Alumni Association Senior Student Research
`Award
`Walter G. Sterling Outstanding Student
`Award
`James B. Plunkett Fellow
`Resident Award
`
`Alpha Omega Alpha Honor Medical
`Society
`University of Texas Medical School
`
`University of Texas Health Science Center
`
`American Brain Tumor Association
`Congress of Neurological Surgeons
`
`10
`
`
`
`Replimune Limited Ex. 2023 - Page 10
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`1994
`
`2001
`2002
`
`2005
`
`2007
`
`2007
`
`American Academy of Neurological
`Surgeons Honorable Mention
`Charles B. Wilson Award
`New Approaches to Brain Therapy
`(NABTT) Award
`Inducted as Fellow
`
`Grass Foundation Award in Neurosurgery
`
`Lawrence Mervis, M.D. Resident Teacher of
`the Year Award
`
`2008
`
`Farber Award in Neuro-oncology
`
`2011
`
`Distinguished Alumnus Award
`
`2013
`
`2018
`
`UTEP Gold Nugget Award
`
`Victor Levin Award Recipient
`
`
`Report of Funded and Unfunded Projects
`
`Funding Information
`
`American Academy of Neurological
`Surgeons
`National Brain Tumor Foundation
`National Brain Tumor Foundation
`
`American Association for the
`Advancement of Science (AAAS)
`Grass Foundation and Society of
`Neurological Surgeons
`The Ohio State University Medical Center,
`Department of Neurosurgery
`
`Society for Neuro-oncology and American
`Association of Neurological
`Surgery/Congress of Neurological Surgery
`Section on Tumors
`
`Graduate School of Biomedical Sciences,
`University of Texas, Health Sciences
`Center at Houston, TX
`University of Texas at El Paso
`
`Society for Neuro-Oncology/New
`Orleans, Louisiana, USA
`
`
`Past
`
`1992-1994
`
`
`
`1992-1995
`
`
`
`
`1994-1995
`
`
`
`1995-1996
`
`
`
`1996-2000
`
`
`Development of Viral Vectors
`American Brain Tumor Association
`Fellow
`
`Molecular Genetics of Inherited Neurologic Diseases: Sub Project 2: Genetic
`Alteration of Central Nervous System Tumors
`NIH/NINDS / P01NS024279 (PI: Xandra Breakefield, PhD)
`PI
`
`A Novel Gene Therapy for Brain Tumors
`Elsa B. Pardee Foundation
`Co-PI
`
`A Novel Gene Therapy for Brain Tumors
`Oliver and Jenny Donaldson Charitable Trust
`PI
`
`Therapy of Experimental Brain Tumors with Prodrug-Activating Genes: Subproject 2
`NIH/NCI / P01 (PI: Fred Hochberg, MD)
`
`11
`
`
`
`Replimune Limited Ex. 2023 - Page 11
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`1997-1999
`
`
`1999-2000
`
`
`
`1999-2001
`
`
`
`
`1999-2004
`
`
`
`2000-2003
`
`
`2000-2004
`
`
`
`2000-2005
`
`
`
`2000-2005
`
`
`
`2001-2002
`
`
`
`2001-2002
`
`
`
`2001-2003
`
`
`
`
`2002-2003
`
`
`
`
`PI
`
`American Brain Tumor Association
`Mentor to Dr. Richard Chung
`
`Therapy of Brain Tumors with SCH5800 and PTEN Adenoviruses
`Schering-Plough, Sponsored Research Agreement
`PI
`
`Interdisciplinary Development of a Computational Tumor Model
`NIH/NCI /R21CA084509
`PI ($150,000)
`
`
`Herpes Simplex Virus for Hepatic Metastases
`NIH/NCI / R01
`Collaborator
`
`The Wellcome Trust Foundation Travelling Fellowship
`Mentor to Dr. Richard Wade-Martins
`
`Brain Tumor Research at Massachusetts General Hospital (MGH)
`The Carolyn Frye Halloran Fund for Brain Tumor Research
`PI
`
`Pharmacologic Enhancement of Viral Oncolysis: Project 1
`NIH/NCI / P01 (PI: Fred Hochberg, MD)
`PI ($1,000,000)
`
`Imaging Gene Transfer by Transferrin Receptor Expression
`NIH/NCI / R01(PI: James P. Basilion PhD)
`Collaborator
`
`Oncolytic Herpes Simplex Virus (HSV) for Prostate Cancer
`Prestwick Scientific Capital Sponsored Research
`PI
`
`Stem Cells for Brain Tumors
`National Brain Tumor Foundation (C.B. Wilson Award)
`PI
`
`Oncolytic Virus and Immunosuppression in Subhuman Primates: Preclinical Toxicity
`Studies
`The Cleveland Clinic Foundation Award “Finding a Cure for Glioblastoma”
`PI
`
`Intra-arterial Oncolytic Virus (OV) and Immunosuppression in Subhuman Primates
`Accelerate Brain Cancer Cure, Inc
`PI
`
`
`12
`
`
`
`Replimune Limited Ex. 2023 - Page 12
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`2002-2003
`
`
`
`2002-2004
`
`
`2002-2004
`
`
`
`2002-2003
`
`
`
`2002-2005
`
`
`
`2003-2008
`
`
`
`
`2005-2007
`
`
`
`
`
`2005-2007
`
`
`
`2005-2008
`
`
`
`2005-2012
`
`
`
`
`2005-2009
`
`
`
`2006-2010
`
`
`
`Stem Cells for Brain Tumors
`National Brain Tumor Foundation (NABTT Award)
`PI
`
`American Brain Tumor Association
`Mentor to Dr. Giulia Fulci
`
`Biology of Tau-Associated Dementias Studied with HSV Amplicons
`Harvard Center for Neuroregeneration and Repair
`PI
`
`Gene Engineering of Nerve Stem Using HSV Amplicon Vector
`NIH/NINDS / R21NS044514
`Co-PI ($200,000)
`
`HSV Amplicon Vectors for Cerebral Ischemia
`R01NS041571 (NIH/NINDS)
`PI ($750,000)
`
`Interdisciplinary Modeling of Tumor Complexity
`NIH-BRP/NCI / R01CA085139
`PI ($3,200,000)
`
`
`Dose Response and Dynamics of Ultrasound Mediated Blood-Brain Barrier (BBB)
`Opening
`NIH/NINDS - Stroke Small Business Technology Transfer Grant (STTR) Perfusion
`Technology, LLC / R41NS052989
`PI
`
`Imaging Transcriptional Activation of Gliomas
`NIH/NCI / R21CA114487
`PI ($197,650)
`
`Biology of Tauopathies Studied with HSV Amplicons
`NIH/NINDS / R01NS045961
`PI ($567,116)
`
`A phase Ib study of Adv-Tk + Valacyclovir gene therapy in combination with
`standard radiation therapy for malignant gliomas.
`Advantagene, Inc /
`PI
`
`OSU Comprehensive Cancer Center Support Group
`NIH/NCI / P30CA016058
`Senior Leader OSU Comprehensive Cancer Center
`
`Early Therapeutics Development with a Phase II Emphasis
`NIH/NCI / N01-CM-62207
`Collaborator
`
`13
`
`
`
`Replimune Limited Ex. 2023 - Page 13
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`2006-2011
`
`
`
`2006-2011
`
`
`
`2007-2008
`
`
`
`2007-2008
`
`
`
`2007-2009
`
`
`2007-2009
`
`
`
`2007-2010
`
`
`
`
`2007-2010
`
`
`
`2007-2012
`
`
`
`
`
`2008-2009
`
`
`
`2008-2010
`
`
`
`2008-2011
`
`
`Imaging of Gene Expression in Glioblastoma
`NIH/NCI - Case Western Reserve Univ. / R01CA109620 (PI: Basilion)
`Site PI ($35,500)
`
`Gene Therapy for Brain Tumors
`NIH/NCI/MGH / P01CA069246 (PI: Hochberg)
`Site PI ($179,599)
`
`Validation of GSK-3 as an Anti-Invasive Target in Glioma
`National Brain Tumor Foundation (NBTF)
`PI
`
`Glioma ECM modulation to enhance OV therapy
`American Association of Neurological Surgeons
`Mentor to Dr. Kazuhiko Kurozumi
`
`Investigation the Role of GSK-3 in Glioma Invasion
`American Brain Tumor Association
`Mentor to Dr. M. Oskar Nowicki
`HSV Amplicon Vectors for Neuroscience Research
`NIH/NIMH / R21MH082421
`PI ($247,500)
`
`A Phase I/II clinical trial to evaluate dose limiting toxicity and efficacy of
`instralesional administration of REOLYSIN® for the treatment of patients with
`histoligcally confirmed recurrent malignant gliomas.
`Oncolytics Biotech, Inc. / 10040176: REO 007.1
`PI
`
`Allergic Conditions Susceptibility Polymorphisms and Glioma Risk
`NIH/NCI / R01CA122163
`Co-Investigator
`
`Development of an Oncoltyic Virus with Prodrug-Activating Gene Therapy
`Alliance for Cancer Gene Therapy (ACGT)
`PI ($181,818)
`The goals of this proposal are to 1) perform preclinical toxicity studies in HSV1-
`susceptible mice and potentially marmosets and 2) implement three clinical phase I
`studies.
`
`The Ivy-Genomics Based Medicine (GBM) Project
`Translational Genomics Research Institute / IVY Foundation
`PI ($178,000)
`
`HSV Vector Platform for Cell-Based Delivery of Oncolytic Adenoviruses to Gliomas
`NIH/NINDS/R21NS063290
`PI ($239,825)
`
`Combination of Cilengitide and Oncolytic HSV: a toxicology study for brain tumors
`
`14
`
`
`
`Replimune Limited Ex. 2023 - Page 14
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`
`
`2008-2013
`
`
`
`
`2008-2013
`
`
`
`
`
`2008-2013
`
`
`
`
`
`2008-2015
`
`
`
`
`
`2009-2014
`
`
`
`
`
`
`2010-2013
`
`
`
`National Institutes of Health/National Inst of Neurological Disorders and Stroke
`(NIH/NINDS) K01NS059575
`Mentor to Dr. Balveen Kaur
`
`A Phase III randomized study of neuradiab in combination with external beam
`radiation and temozolomide versus external beam radiation and temozolomide in
`patients with newly diagnosed glioblastoma multiforme.
`Bradmer Pharmaceuticals
`PI
`
`Preclinical Toxicity Evaluation of a Potent Oncoltyic Virus
`NIH/NINDS / U01NS061811
`PI ($965,661)
`The objectives of this study are to 1) perform bioequivalency studies of
`rQNestin34.5v.2 and of reagents and standard operating protocol for future clinical
`grade production and to determine preclinical toxicity of rQNestin34.5 in vitro and in
`animal models; 2) validation of therapeutic efficacy and safety monitoring with
`rQNestin34.5v; 3) validation of safety monitoring with rQNestin34.5v.2 in presence
`of CPA; 4) Final toxicology/biodistribution study with GMP-grade clinical lot. The
`successful pursuit of milestone 4 will permit us to approach regulatory agencies to
`start a phase I trial in patients with recurrent malignant glioma using rQNestin34.5v.2
`+ CPA immomunodulation and subsequently a phase I trial in newly diagnosed
`glioma using rQNestin34.5v.2 + CPA immomunodulation + standard treatment.
`
`Enhancing Viral Oncolysis with Vasculostatin Gene Delivery
`NIH/NCI / R01CA150153 (PI: Kaur)
`Co-Investigator
`The ultimate goal of this project is to understand the contribution of Vstat120
`expressing oncolytic viruses on OV propagation, tumor biology and anti-tumor
`efficacy.
`
`Preclinical Toxicity Evaluation of a Potent Oncolytic Virus
`7U01NS061811-05
`PI ($1,702,064)
`The goal of this study is to obtain the needed preclinical toxicology and
`biodistribution data to justify as phase I trial in humans of a novel OV in humans with
`recurrent glioma
`
`Research Education Program for Residents/Fellows in Neurology and Neurosurgery
`at The Ohio State University
`NIH/NINDS / R25NS065734
`PI ($50,935)
`The purpose of this proposed R25 training program for neurologists and
`neurosurgeons at OSU is to prepare carefully selected residents (from neurosurgery,
`neurology, radiology and pathology) for future careers in research leading to
`improved understanding, diagnosis and treatment of neurological diseases.
`
`Networks of Tissue Source (TSS) in support of The Cancer Genome Atlas (TCGA)
`Program
` (NIH/NCI/ Case Western Reserve Univ / HHSN261201000057C / RES505695
`
`15
`
`
`
`Replimune Limited Ex. 2023 - Page 15
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`2013-2018
`
`
`
`
`
`2014-2015
`
`
`
`
`
`2014-2015
`
`
`
`
`
`2014-2018
`
`
`
`
`
`2015-2017
`
`
`
`
`
`
`
`Current
`
`2012-2022
`
`
`
`
`2013-2024
`
`
`
`
`Site-PI ($45,185)
`
`The Role of Cidofovir and structural analogs as Adjuvant Therapy for Glioblastoma
`1R01CA184283-01
`Co-Investigator (PI: Cobbs)
`In this study, we will use the anti-viral drug Cidofovir and analogs to test whether this
`can prevent glioblastoma formation
`
`Intraoperative detection and ablation of microscopic residual cancer in the tumor bed
`Lumicell Diagnostics Inc./NSF (1152489)
`PI ($57,338)
`The goal of this study is to validate the utility of Lumicell Surgical System as a
`supporting device in surgery.
`
`Combining oncolytic virus immunostimulation with PD-1 checkpoint inhibition
`Massachusetts General Hospital/NIH-NCI / 5P50CA165962-02
`PI (Pilot Study)
`This pilot study watches the effects of combining oncolytic virus immunostimulation
`with PD-1 checkpoint inhibition.
`
`Investigating the cytomegalovirus link to glioblastoma using a novel mouse model
`NIH / 1R01CA195532-01
`PI ($396,328)
`This study investigates the cytomegalovirus link to glioblastoma using a novel mouse
`model.
`
`Chimeric Anti-Fibulin-3 Reagents For Targeted Therapy Of Glioblastoma
`1R21NS091436-01
`Co-Investigator (PI: Viapiano)
`This study investigates chimeric anti-fibulin-3 reagents for targeted therapy of
`Glioblastoma.
`
`
`Experimental Therapeutics and BioMonitoring for Brain Tumors
`5P01CA069246-17
`
`Co-PI (Co-PI: Breakefield/Chiocca): Chiocca PI of Project 1
`This project focuses on evaluating whether microvesicle-derlved viral and key cellular
`transcripts prime the microenvironment of the infected glioma to allow for more
`efficient replication and distribution of the OV and therapeutic transgenes carried by
`the OV
`
`Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas
`1P01CA163205-01A1
`Co-PI (Co-PI: Caligiuri/Chiocca); Chiocca PI of Project 2
`The objectives of this study are to determine if inhibition of HDAC6 leads to
`enhanced oHSV replication in a panel of freshly excised human glioma spheroids
`(GSs) in vitro and in vivo, whether there is cross-talk between type 1 interferon
`
`16
`
`
`
`Replimune Limited Ex. 2023 - Page 16
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`2014-2019
`
`
`
`
`
`
`2015-2020
`
`
`
`
`2016-2021
`
`
`
`
`signaling and HDAC6 activity in oHSV infected glioma cells and GS, and whether
`the observed antiviral function of HDAC6 relates to its action on entry/post-entry
`oHSV intracellular trafficking.
`
`MicroRNA128 Regulation of Polycomb Repressor Complexes1 and 2 in
`Glioblastoma
`1R01CA176203-01A1
`Co-Investigator (PI: Godlewski)
`This study attempts to determine a link between expression of certain molecules
`known as microRNA-128 and
`cancer stem cells (cancer initiating cells) of glioblastoma, the most lethal brain tumors
`among adult patients.
`
`MicroRNAs in glioma invasion and therapy
`NIH-NCI / 1R01CA169199-01A1
`Co-Investigator (PI: Godlewski)
`This study investigates MicroRNAs in glioma invasion and therapy.
`
`A CEST-BRI Reporter Gene for Image Guided Oncolytic Virotherapy
`NIH-NCI R01CA203873
`Co-Investigator (PI: Farrar)
`This project we propose to develop and optimize a MRI reporter gener that can be
`engineered into oncolytic viruses and allow for the non-invasive imaging oncolytic
`virotherapy.
`
`
`
`Report of Local Teaching and Training
`
`Teaching of Students in Courses
`
`1996-1997
`
`
`1998
`
`
`
`2011
`
`
`
`2011
`
`
`
`2011
`
`Genetics 208: Gene Therapy
`Undergraduate, Graduate, Postgraduate
`students
` (average number of students 30)
`Gene Therapy
`
`Graduate students
`(average number of students 20)
`
`Integrated Biomedical Science Dissertation
`Res: 999
`Graduate students
`(average number of students 2 per quarter)
`
`Integrated Biomedical Science Dissertation
`Individual Studies 793
`Graduate students
`(average number of students 2 per quarter)
`“Gene and viral therapy clinical trials for
`
`Harvard Medical School
`Two hour preparation / one hour
`lecture
`
`Harvard Biological and Biomedical
`Science (BBS) Workshop
`Two hour preparation / one hour
`lecture
`
`The Ohio State University, College of
`Medicine
`Spring (18 credit hrs), Summer (18
`credit hrs), Autumn (18 credit hrs),
`Winter (18 credit hrs)
`
`The Ohio State University, College of
`Medicine
`Summer (15 credit hrs)
`
`The Ohio State University, College of
`
`17
`
`
`
`Replimune Limited Ex. 2023 - Page 17
`Transgene and Bioinvent International AB v. Replimune Limited
`PGR2022-00014 - U.S. Patent No. 10,947,513
`
`

`

`
`
`
`
`
`2013
`
`
`
`2019
`
`brain tumors”
`Neuroscience Graduate School Program
`Class
`“Patient Safety and Clinical
`Communications”
`Interns
`
`
`“Peripheral Nerves”
`Sub-I’s
`
`Medicine
`Two hour preparation / one hour
`lecture
`
`Society of Neurological Surgeons
`Bootcamp, Tufts Medical Center
`30 minute lecture
`
`2 Hour Preparation/ one hour lecture
`Brigham and Women’s Hospital
`
`2004-2012
`
`Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)
`1995-2004
`Attending Physician, Neurosurgical
`Massachusetts General Hospital
`Residents
`(20 hours/week)
`Attending Physician, Neurosurgical
`The Ohio State University Wexner
`Residents
`Medical Center (20 hours/week)
`Attending Physician, Neurosurgical
`Brigham & Women’s Hospital
`Residents
`(20 hours/week)
`
`
`2012-
`
`
`Clinical Supervisory and Training Responsibilities
`
`2009-2011
`
`Neurosurgical Oncology Fellow/ Wexner
`Medical Center, Columbus, OH
`
`
`
`10 hours/week
`
`Laboratory and Other Research Supervisory and Training Responsibilities
`
`2009-
`2012-
`
`
`
`
`
`
`MD/PhD student (Richard Price)
`MSTP student (Stephen Bergin)
`
`
`Mentorship, 5 hours/week
`Mentorship, 5 hours/week
`
`Formally Supervised Trainees
`Research
`1992-1995
`
`Ming X. Wei, Ph.D /
`
`1993
`
`1993-1994
`
`1993-1994
`
`1994-1995
`
`1996-1999
`
`1996-20